company background image
ALSE

Sensorion ENXTPA:ALSEN Stock Report

Last Price

€0.47

Market Cap

€37.4m

7D

1.6%

1Y

-76.2%

Updated

22 May, 2022

Data

Company Financials +
ALSEN fundamental analysis
Snowflake Score
Valuation1/6
Future Growth1/6
Past Performance0/6
Financial Health4/6
Dividends0/6

ALSEN Stock Overview

Sensorion SA, a clinical-stage biopharmaceutical company, develops therapies for the treatment of inner ear disorders in France.

Sensorion Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Sensorion
Historical stock prices
Current Share Price€0.47
52 Week High€2.29
52 Week Low€0.45
Beta2.47
1 Month Change-15.77%
3 Month Change-20.07%
1 Year Change-76.22%
3 Year Change-60.57%
5 Year Change-91.97%
Change since IPO-89.65%

Recent News & Updates

Shareholder Returns

ALSENFR BiotechsFR Market
7D1.6%2.3%-1.3%
1Y-76.2%-39.0%-5.4%

Return vs Industry: ALSEN underperformed the French Biotechs industry which returned -39% over the past year.

Return vs Market: ALSEN underperformed the French Market which returned -5.4% over the past year.

Price Volatility

Is ALSEN's price volatile compared to industry and market?
ALSEN volatility
ALSEN Average Weekly Movement16.4%
Biotechs Industry Average Movement8.8%
Market Average Movement6.1%
10% most volatile stocks in FR Market10.4%
10% least volatile stocks in FR Market3.6%

Stable Share Price: ALSEN is more volatile than 90% of French stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: ALSEN's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of French stocks.

About the Company

FoundedEmployeesCEOWebsite
200939Nawal Ouzrenhttps://www.sensorion.com

Sensorion SA, a clinical-stage biopharmaceutical company, develops therapies for the treatment of inner ear disorders in France. It engages in developing USHER-GT, a gene therapy development program to restore inner ear function for patients suffering from usher syndrome Type 1; OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. The company’s pipeline includes various products in development stage for restoring, treating, and preventing inner ear related disorders.

Sensorion Fundamentals Summary

How do Sensorion's earnings and revenue compare to its market cap?
ALSEN fundamental statistics
Market Cap€37.45m
Earnings (TTM)-€15.14m
Revenue (TTM)€4.35m

8.6x

P/S Ratio

-2.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALSEN income statement (TTM)
Revenue€4.35m
Cost of Revenue€0
Gross Profit€4.35m
Other Expenses€19.49m
Earnings-€15.14m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

Oct 31, 2022

Earnings per share (EPS)-0.19
Gross Margin100.00%
Net Profit Margin-348.08%
Debt/Equity Ratio0.0%

How did ALSEN perform over the long term?

See historical performance and comparison

Valuation

Is Sensorion undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


0.85x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ALSEN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ALSEN's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: ALSEN is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.

PE vs Market: ALSEN is unprofitable, so we can't compare its PE Ratio to the French market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALSEN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ALSEN is good value based on its PB Ratio (0.8x) compared to the FR Biotechs industry average (2.6x).


Future Growth

How is Sensorion forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-24.2%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALSEN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ALSEN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ALSEN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ALSEN's revenue (13.9% per year) is forecast to grow faster than the French market (5.8% per year).

High Growth Revenue: ALSEN's revenue (13.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ALSEN's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Sensorion performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-7.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ALSEN is currently unprofitable.

Growing Profit Margin: ALSEN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ALSEN is unprofitable, and losses have increased over the past 5 years at a rate of 7.2% per year.

Accelerating Growth: Unable to compare ALSEN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALSEN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).


Return on Equity

High ROE: ALSEN has a negative Return on Equity (-34.36%), as it is currently unprofitable.


Financial Health

How is Sensorion's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ALSEN's short term assets (€56.9M) exceed its short term liabilities (€10.5M).

Long Term Liabilities: ALSEN's short term assets (€56.9M) exceed its long term liabilities (€4.5M).


Debt to Equity History and Analysis

Debt Level: ALSEN is debt free.

Reducing Debt: ALSEN has no debt compared to 5 years ago when its debt to equity ratio was 23.4%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if ALSEN has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ALSEN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Sensorion current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALSEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALSEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALSEN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALSEN's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ALSEN has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.6yrs

Average management tenure


CEO

Nawal Ouzren (42 yo)

5.08yrs

Tenure

Ms. Nawal Ouzren serves as an Independent Non-Executive Director at Croda International Plc since February 1, 2022. She has been Chief Executive Officer of Sensorion SA (Sensorion SAS) since April 12, 2017...


Leadership Team

Experienced Management: ALSEN's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.


Board Members

Experienced Board: ALSEN's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Sensorion SA's employee growth, exchange listings and data sources


Key Information

  • Name: Sensorion SA
  • Ticker: ALSEN
  • Exchange: ENXTPA
  • Founded: 2009
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: €37.446m
  • Shares outstanding: 79.67m
  • Website: https://www.sensorion.com

Number of Employees


Location

  • Sensorion SA
  • 375, rue du Professeur Joseph Blayac
  • Montpellier
  • Languedoc-Roussillon
  • 34080
  • France

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/22 00:00
End of Day Share Price2022/05/20 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.